• Skip to primary navigation
  • Skip to main content
  • Skip to footer
MotherToBaby

MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

Hide Search
Shopping Cart
Show SearchSearch
866.626.6847
  • About
    • Our Work
    • Our Team
    • Our Partners
    • Our Impact
  • Exposures
    • Pregnancy and Breastfeeding Exposures
    • Fact Sheets
    • Baby Blogs
    • Podcasts
    • Interactive Tool
    • Other Educational Tools
    • LactRx App
  • Studies
    • Ongoing Studies
    • What’s Involved?
    • Join Now
    • Refer a Patient
    • Health Providers
    • Pharma Industry
    • Publications
  • Health Professionals
    • Patient Education and Provider Resources
    • Refer a Patient
    • Request Materials
    • Meetings
    • FAQs
    • OTIS Membership
  • Media
    • Media Requests
    • Press Releases
    • eNews Sign Up
  • In Your Area
  • OTIS
    • About OTIS
    • OTIS Membership
    • Annual Meeting
    • Member Log-In
  • Donate
  • Contact
  • Show SearchSearch

IODINE-131

October 1, 2022

Selected References:

  • Alexander EK, et al. 2017. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid, 27(3):315-389.
  • Garsi JP, et al. 2008. Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies. J Nucl Med, 49(5):845-852.
  • Hammami MM, et al. 1996. Radioiodine breast uptake in nonbreastfeeding women: clinical and scintigraphic characteristics. J Nucl Med, 37:26-31.
  • Hyer S, et al. 2002. Testicular dose and fertility in men following I(131) therapy for thyroid cancer. Clin Endocrinol (Oxf), 56:755-758.
  • 2008. Radiation dose to patients from radiopharmaceuticals – Addendum 3 to ICRP Publication 53. ICRP Publication 106. Ann ICRP, 38(1-2):1-197.
  • Iijima S, 2021. Effects of fetal involvement of inadvertent radioactive iodine therapy for the treatment of thyroid diseases during an unsuspected pregnancy. European Journal of Obstetrics & Gynecology and Reproductive Biology, 259:54-58.
  • Ko KY, et al. 2016. Pregnancy outcome after I-131 therapy for patients with thyroid cancer: A nationwide population-based cohort study. Medicine (Baltimore), 95(5):e2685.
  • LeideSvegborn S, et al. 2016. Excretion of radionuclides in human breast milk after nuclear medicine examinations. Biokinetic and dosimetric data and recommendations on breastfeeding interruption. Eur J Nucl Med Mol Imaging, 43:808-821.
  • Masiuk S, et al. 2022. Assessment of internal exposure to 131I and short-lived radio iodine isotopes and associated uncertainties in the Ukrainian cohort of persons exposed in utero. Journal of Radiation Research, 63(3):364–375.
  • Mattsson S, et al. 2021. X-ray and molecular imaging during pregnancy and breastfeeding when should we be worried? Radiation Protection Dosimetry, 195(3–4):339-346.
  • Motavalli LR, et al. 2016. Fetal and maternal dose assessment for diagnostic scans during pregnancy. Phys Med Biol, 61(9):3596-3608.
  • Radacic-Aumiler M, et al. 2016. No adverse effects after radioiodine treatment at 3 weeks of pregnancy. Clin Nucl Med, 41(12):964-965.
  • Read CH Jr, et al. 2004. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves’ patients. J Clin Endocrinol Metab, 89:4229-4233.
  • Schlumberger M, et al. 1996. Exposure to radioactive Iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med, 37:606–612.
  • Sioka C, 2011. Fotopoulos A. Effect of I-131 therapy on gonads and pregnancy outcome in patients with thyroid cancer. Fertil Steril, 95(5):1552-1559.
  • Tatham LM, et al. 2002. Population exposures to I-131 releases from Hanford Nuclear Reservation and preterm birth, infant mortality, and fetal deaths. Int J Hyg Environ Health, 205:41-28.
  • Zhang L, et al. 202. The effect of I-131 therapy on pregnancy outcomes after thyroidectomy in patients with differentiated thyroid carcinoma: a meta-analysis. Endocrine, 73:301-307.

Footer

               

Hot Links

  • Home
  • Exposures
  • Fact Sheets
  • Baby Blogs
  • Podcasts
  • Pregnancy Studies
  • Join a Study Now
  • Healthcare Professionals
  • Refer a Patient
  • Request Materials
  • News
  • Donate
  • Ask An Expert

Current Studies

  • Ankylosing Spondylitis
  • Constipation
  • Coronavirus (COVID-19)
  • Eczema (Moderate-to-Severe)/Atopic Dermatitis
  • Hidradenitis Suppurativa
  • Lupus
  • Multiple Sclerosis
  • Non-Radiographic Axial Spondyloarthritis
  • Psoriasis
  • Psoriatic Arthritis

Contact

Exposure Information Service
866.626.6847

Pregnancy Studies
877.311.8972

Media Inquiries
619.368.3259
nchavez@mothertobaby.org

MotherToBaby, a service of the Organization of Teratology Information Specialists

Copyright © 2025 The Organization of Teratology Information Specialists

  • Accessibility
  • Privacy
  • Terms
  • Site Map
^

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.